HUTCHMED (China) (HCM) Non-Current Deffered Revenue (2015 - 2026)
HUTCHMED (China) (HCM) posted quarterly Non-Current Deffered Revenue of $10.6 million for Q2 2026, down 65.64% year-over-year from $30.8 million in Q2 2025, and down 47.46% quarter-over-quarter from $20.1 million in Q4 2025.
HUTCHMED (China) (HCM) Non-Current Deffered Revenue (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HCM) has reported Non-Current Deffered Revenue for 11 consecutive years, with $10.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Deffered Revenue fell 65.64% year-over-year to $10.6 million; the TTM figure through Jun 2026 stood at $10.6 million (down 65.64% YoY), while the FY2025 annual figure was $20.1 million, changed N/A from the prior year.
- Non-Current Deffered Revenue slipped to $10.6 million in Q2 2026 per HCM's latest filing, from $20.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $97.2 million in Q2 2023 and bottomed at $190000.0 in Q4 2022.
- Historically, Non-Current Deffered Revenue has averaged $36.6 million across 5 years, with a median of $25.5 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue slumped 37.61% — and 2026, when it slumped 65.64%.
- HUTCHMED (China)'s Non-Current Deffered Revenue stood at $190000.0 in 2022, then jumped by 51045.26% to $97.2 million in 2023, then tumbled by 37.61% to $60.6 million in 2024, then sank by 66.79% to $20.1 million in 2025, then slumped by 47.46% to $10.6 million in 2026.
- Business Quant data shows HCM's Non-Current Deffered Revenue at $10.6 million in Q2 2026, $20.1 million in Q4 2025, and $30.8 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | HUTCHMED (China) | 2.19 Bn | 2.19 Bn | - | 10.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.58 Mn |
| Dec 31, 2025 | 20.13 Mn |
| Jun 30, 2025 | 30.79 Mn |
| Jun 30, 2024 | 60.63 Mn |
| Jun 30, 2023 | 97.18 Mn |
| Dec 31, 2022 | 190,000.00 |
| Dec 31, 2020 | 484,000.00 |
| Dec 31, 2019 | 133,000.00 |
| Dec 31, 2018 | 408,000.00 |
| Jun 30, 2018 | 924,000.00 |
| Dec 31, 2017 | 1.99 Mn |
| Dec 31, 2016 | 131,000.00 |
| Dec 31, 2015 | 2.13 Mn |